

Cite this: *Org. Biomol. Chem.*, 2011, **9**, 62

www.rsc.org/obc

## COMMUNICATION

## Total syntheses of subereamollines A and B†

James W. Shearman,<sup>a</sup> Rebecca M. Myers,<sup>a</sup> James D. Brenton<sup>b</sup> and Steven V. Ley<sup>\*a</sup>

Received 27th August 2010, Accepted 27th September 2010


DOI: 10.1039/c0ob00636j

The first total syntheses of (+)- and (–)-subereamollines A and B are reported. The enantiomeric forms of the natural products were obtained by preparative chiral HPLC separation of the corresponding racemates.

Marine sponges of the order Verongida are a rich source of bromotyrosine-derived natural products. Many of these compounds are biologically active and exhibit a range of activities including antiviral,<sup>1</sup> antimicrobial,<sup>2</sup> antifungal,<sup>3</sup> Na<sup>+</sup>/K<sup>+</sup> ATPase inhibition,<sup>4</sup> anti-HIV,<sup>5</sup> HDAC inhibition,<sup>6</sup> antifouling,<sup>7</sup> histamine H3 antagonism,<sup>8</sup> mycothiol S-conjugate amidase inhibition,<sup>9</sup> and isoprenylcysteine carboxy methyltransferase (Icmt) inhibition.<sup>10</sup> Anticancer activity has also been reported, for example, the spirocyclohexadienylisoxazoline purealidin P and Q are cytotoxic against murine lymphoma K1210 (IC<sub>50</sub> 2.8 and 0.95 μg mL<sup>−1</sup> respectively) and human epidermal carcinoma KB (nasopharynx) (IC<sub>50</sub> 7.6 and 1.2 μg mL<sup>−1</sup> respectively) cell lines.<sup>11,12</sup> Other structurally related compounds have also exhibited cytotoxic properties.<sup>13</sup>

When the extracts of the Red Sea sponge *Suberea mollis* were reinvestigated recently, two new bromotyrosine-derived secondary metabolites containing the spirocyclohexadienylisoxazoline moiety were identified; subereamollines A (**1**) and B (**2**) (Scheme 1).<sup>14</sup> Small quantities (2–5 mg) were isolated and **1** was found to have modest antimicrobial activity against *Staphylococcus aureus*, however, their cytotoxic activity was not reported. As part of our ongoing investigation into the anticancer properties of bromotyrosine-derived natural products,<sup>15</sup> the subereamollines were attractive synthetic targets.

Both **1** and **2** contain a 2,4-dibromo-1-hydroxy-3-methoxyspirocyclohexadienylisoxazole moiety attached to a carbamate containing side chain *via* an amide linkage. Although not explicitly stated in the isolation paper,<sup>14</sup> the absolute stereochemistries at C(1) and C(6) were determined to be (*R*) and (*S*) based on the optical rotations of **1** {[α]<sub>D</sub> +156.5 (*c* 0.55, MeOH)} and **2** {[α]<sub>D</sub> +22.9 (*c* 6.25, CH<sub>2</sub>Cl<sub>2</sub>)}. These data



Scheme 1 Retrosynthetic analysis of subereamollines A (**1**) and B (**2**).

correlated with that reported for (+)-aerolithionin {[α]<sub>D</sub> +210 (*c* 1.7, MeOH)} whose absolute configuration was determined by X-ray crystallography and circular dichroism (CD) spectroscopy.<sup>16</sup>

We envisaged that **1** and **2** could be synthesised by coupling spiro acid (±)-**3** with either amine **4** or **5** (Scheme 1). Interestingly, **3** has been isolated from the marine sponge *Pseudoceratina* sp. as an optically pure isomer with its absolute configuration defined as 1*S*,6*R* by CD analysis.<sup>17</sup> However, the only reported synthesis of (±)-**3** is as an intermediate during the synthesis of purealin.<sup>18</sup> The corresponding methyl ester **6**<sup>19–22</sup> has been synthesised in an enantioenriched form (74% *ee*) *via* an asymmetric oxidative spirocyclisation which required a multi-step synthesis of a chiral auxiliary.<sup>23</sup> An alternative approach led to enantiopure **6** by resolution of (±)-**6** by derivatisation with (–)-camphanic chloride.<sup>24</sup>


Our approach to the naturally occurring enantiomers of **1** and **2** involved chiral HPLC separation of the corresponding racemates as this would require no additional synthetic operations and would also deliver enantiopure material required for biological screening.

Aldehyde **8** was prepared in 92% yield over two steps *via* bromination of 2-hydroxy-4-methoxybenzaldehyde (**7**) with *N*-bromosuccinimide and subsequent benzyl protection of the phenolic oxygen (Scheme 2). Conversion of **8** into the corresponding azlactone **9** was achieved by heating the aldehyde with *N*-acetylglycine and sodium acetate in the presence of acetic anhydride (Erlenmeyer conditions).<sup>25</sup> Saponification of the crude azlactone **9** with barium hydroxide and subsequent condensation with *O*-benzylhydroxylamine furnished the carboxylic

<sup>a</sup>Department of Chemistry, Lensfield Road, University of Cambridge, Cambridge, United Kingdom CB2 1EW. E-mail: svl1000@cam.ac.uk; Fax: +44 1223 3363968


<sup>b</sup>Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, United Kingdom CB2 0RE

† Electronic supplementary information (ESI) available: experimental procedures for the preparation of compounds **1–6** and **8–14** and full characterisation of these compounds. <sup>1</sup>H and <sup>13</sup>C NMR spectra of **1** and **2**. CCDC reference numbers 787666 and 787667. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c0ob00636j



Scheme 2 Synthesis route to 1 and 2.

acid **10** in 49% yield. This yield did not improve when **9** recrystallised from acetone was used. Furthermore, oxime **11** was discovered to be a major by-product (22% yield), which may have arisen from reversion of **9** to its parent aldehyde under the basic conditions and subsequent condensation with the *O*-benzylhydroxylamine. Azlactones are known to hydrolyse efficiently under acidic conditions (e.g. 3 N HCl, reflux, 24 h)<sup>26</sup> to give  $\alpha$ -keto acid derivatives which can then be converted to the corresponding oxime acids.<sup>27</sup> However, when these conditions were applied to **9** this unexpectedly resulted in the loss of the phenolic benzyl protecting group and spontaneous lactonisation to produce coumarin **12** (in 68% yield) as the only observable product.<sup>28</sup>




The cyclisation precursor, oxime methyl ester **13**, was obtained first by treatment of **10** with trimethylsilyldiazomethane to obtain its methyl ester then removal of the benzyl groups *via* hydrogenolysis over palladium black.<sup>18</sup> The oxidative cyclisation to transform **13** to spiroisoxazoline (±)-**14** in other syntheses has been achieved with thallium(III) trifluoroacetate,<sup>19</sup> electroorganic oxidation<sup>20</sup> and *N*-bromosuccinimide.<sup>18</sup> However, we found that iodobenzene diacetate<sup>21,22</sup> was the most convenient reagent on this occasion since the crude material could be taken on directly to the next step following an aqueous work up. Diastereoselective reduction of (±)-**14** with Zn(BH<sub>4</sub>)<sub>2</sub><sup>29</sup> furnished the desired *trans*-isomer (±)-**6a** in a 2.03:1 *dr* over the undesired *cis*-isomer (±)-**6b**. X-Ray crystallographic analysis confirmed the relative stereochemistry of each isomer.<sup>30</sup> The methyl ester was then hydrolysed with lithium hydroxide to furnish (±)-**3** in an overall yield of 11% from aldehyde **7**.

Putrescine (**15**) and cadaverine (**16**) were converted to the amine coupling partners **4** and **5** in one step *via* dropwise addition of ethyl phenyl carbonate<sup>31</sup> to minimize *bis*-carbamylation. Spiro acid (±)-**3** was then coupled to amine **4** or **5** in the presence of *N,N'*-dicyclohexylcarbodiimide (DCC) and hydroxybenzotriazole

(HOBt) to afford the natural products subereamolline A (**1**) and B (**2**) respectively in 91% and 75% yield as a racemic mixture. Upon reinvestigation of this coupling step, it was found that the use of the coupling agent propylphosphonic anhydride (<sup>®</sup>T3P) furnished **1** and **2** in 96% and 97% yields respectively.

The <sup>1</sup>H and <sup>13</sup>C NMR spectra of synthetic **1** and **2** matched those of the natural materials.<sup>32</sup> We have also established that the originally reported <sup>13</sup>C chemical shift assignments for C-2 ( $\delta_c$  122.9) and C-4 ( $\delta_c$  114.3) should be switched on the basis of COLOC NMR experiments reported for related spirocyclised products.<sup>33</sup> This is also supported by the HMBC correlations in the natural products.<sup>34</sup>

The enantiomeric forms of ( $\pm$ )-**1** and ( $\pm$ )-**2** were separated using preparative chiral HPLC (CHIRALPAK AD-H column and 10% *i*Pr<sub>2</sub>OH in hexane at a flow rate of 5 mL min<sup>-1</sup>) (Scheme 2). The optical rotations of (+)-**1** ( $t$  = 40.3 min) and (+)-**2** ( $t$  = 48.3 min) agreed with those observed for natural **1** and **2**. To confirm the absolute stereochemistries at C(1) and C(6), (+)-**6** ( $t$  = 30.9 min) and (–)-**6** ( $t$  = 32.9 min) were obtained from chiral HPLC separation of ( $\pm$ )-**6** (Scheme 3).<sup>35</sup> Hydrolysis of (+)-**6** and (–)-**6** under the basic conditions furnished acids (+)-**3** and (–)-**3** that were then coupled with amines **4** and **5** respectively. HPLC analysis of the products showed them to be (+)-**1** and (–)-**2** respectively (see Electronic Supplementary Information), thus confirming the original stereochemical assignments at C(1) and C(6).



Scheme 3

MTS assays<sup>36</sup> were performed to evaluate the cytotoxic activity of compounds ( $\pm$ )-**1**, ( $\pm$ )-**2**, (+)-**1**, (+)-**2**, **12** and **13** against an ovarian cancer (SK-OV-3) cell line. Following 48 h treatment, none of the compounds exhibited cytotoxic activities up to a concentration of 100  $\mu$ M.

In conclusion, the first total syntheses of the bromotyrosine-derived natural products subereamolline A (**1**) and B (**2**) have been reported. The enantiomeric forms of **1** and **2** were obtained by chiral HPLC separation and, in addition, the stereochemistries at C(1) and C(6) in the naturally occurring enantiomers (+)-**1** and (+)-**2** were confirmed to be *R* and *S* respectively.

## Acknowledgements

We acknowledge the Cambridge Cancer Research UK PhD Training Programme in Medicinal Chemistry for funding (J.W.S.). The authors thank Dr John E. Davies of the X-ray facility of the Department of Chemistry for collecting the crystallographic data and Dr Richard M. Turner for help with preparative chiral HPLC.

## Notes and references

- S. P. Gunasekera and S. S. Cross, *J. Nat. Prod.*, 1992, **55**, 509.
- J. Kobayashi, M. Tsuda, K. Agemi, H. Shigemori, M. Ishibashi, T. Sasaki and Y. Mikami, *Tetrahedron*, 1991, **47**, 6617.
- J.-H. Jang, R. W. M. van Soest, N. Fusetani and S. Matsunaga, *J. Org. Chem.*, 2007, **72**, 1211.
- H. Nakamura, H. Wu and J. Kobayashi, *Tetrahedron Lett.*, 1985, **26**, 4517.
- S. A. Ross, J. D. Weete, R. F. Schinazi, S. S. Wirtz, P. Tharnish, P. J. Scheuer and M. T. Hamann, *J. Nat. Prod.*, 2000, **63**, 501.
- M. W. B. McCulloch, G. S. Coombs, N. Banerjee, T. S. Bugni, K. M. Cannon, M. K. Harper, C. A. Veltri, D. M. Virshup and C. M. Ireland, *Bioorg. Med. Chem.*, 2009, **17**, 2189.
- I. Thironet, D. Daloze and J. C. Braekman, *Nat. Prod. Lett.*, 1998, **12**, 209.
- R. A. K. Mierzwa, M. A. Conover, S. Tozzi, M. S. Puar, M. Patel and S. J. Covan, *J. Nat. Prod.*, 1994, **57**, 175.
- G. M. Nicholas, G. L. Newton, R. C. Fahey and C. A. Bewley, *Org. Lett.*, 2001, **3**, 1543.
- M. S. Buchanan, A. R. Carroll, G. A. Fechner, A. Boyle, M. Simpson, R. Addepalli, V. M. Avery, J. N. A. Hooper, T. Cheung, H. Chen and R. J. Quinn, *J. Nat. Prod.*, 2008, **71**, 1066.
- T. Fujiwara, J.-H. Hwang, A. Kanamoto, H. Nagai, M. Takagi and S.-Y. Kauzo, *J. Antibiot (Tokyo)*, 2009, **62**, 393; P. B. Shinde, Y. M. Lee, H. T. Dang, J. Hong, C.-O. Lee and J. H. Jung, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 6414.
- J. Kobayashi, K. Honma, T. Sasaki and M. Tsuda, *Chem. Pharm. Bull.*, 1995, **43**, 403.
- J. Peng, J. Li and M. T. Hamann, *Alkaloids*, 2005, **61**, 59.
- M. I. Abou-Shoer, L. A. Shaala, D. T. A. Youssef, J. M. Badr and A.-A. M. Habib, *J. Nat. Prod.*, 2008, **71**, 1464.
- J. W. Shearman, R. M. Myers, T. M. Beale, J. D. Brenton and S. V. Ley, *Tetrahedron Lett.*, 2010, **51**, 4812.
- J. A. McMillan, I. C. Paul, Y. M. Goo and K. L. Rinehart Jr, *Tetrahedron Lett.*, 1981, **22**, 39.
- A. Aiello, E. Fattorusso, M. Menna and M. Pansini, *Biochem. Syst. Ecol.*, 1995, **23**, 377.
- G. Zhu, F. Yang, R. Balachandran, P. Höök, R. B. Vallee, D. P. Curran and B. W. Day, *J. Med. Chem.*, 2006, **49**, 2063.
- S. Nishiyama and S. Yamamura, *Tetrahedron Lett.*, 1983, **24**, 3351.
- T. Ogami, Y. Ishikawa and S. Nishiyama, *Heterocycles*, 2003, **61**, 73.
- O. Hoshino, M. Masatoshi and Y. Kohei, *Tetrahedron*, 1996, **52**, 14713.
- T. R. Boehlow, J. J. Harburn and C. D. Spilling, *J. Org. Chem.*, 2001, **66**, 3111.
- M. Murakata, M. Tamura and O. Hoshino, *J. Org. Chem.*, 1997, **62**, 4428.

- 24 T. Ogamino, R. Obata and S. Nishiyama, *Tetrahedron Lett.*, 2006, **47**, 727.
- 25 E. Erlenmeyer, *Justus Liebigs Ann. Chem.*, 1893, **275**, 1.
- 26 B. M. Chanda and R. S. Sulake, *Tetrahedron Lett.*, 2005, **46**, 6461; P. Busca, F. Paradisi, E. Moynihan, A. R. Maguire and P. C. Engel, *Org. Biomol. Chem.*, 2004, **2**, 2684.
- 27 N. Kotoku, H. Tsujita, A. Hiramatsu, C. Mori, N. Koizumi and M. Kobayashi, *Tetrahedron*, 2005, **61**, 7211.
- 28 *Crystal data for 12*:  $C_{10}H_6Br_2O_4$ ,  $M = 349.97$ , orthorhombic, space group  $Pna2(1)$ ,  $a = 8.9710(2)$  Å,  $b = 10.6189(2)$  Å,  $c = 22.6185(6)$  Å,  $V = 2154.69(8)$  Å<sup>3</sup>,  $Z = 8$ ,  $D_c = 2.158$  Mg m<sup>-3</sup>,  $T = 180(2)$  K. The X-ray structure of coumarin **12** has been previously reported. J. J. Harburn, N. P. Rath and C. D. Spilling, *J. Org. Chem.*, 2005, **70**, 6398.
- 29 Prepared using literature procedure. W. J. Gensler, F. A. Johnson and D. B. Sloan, *J. Am. Chem. Soc.*, 1960, **82**, 6074.
- 30 *Crystal data for (±)-6a*:  $C_{11}H_{11}Br_2NO_5$ ,  $M = 397.03$ , triclinic, space group  $P\bar{1}$ ,  $a = 6.5189(1)$  Å,  $b = 10.7194(2)$  Å,  $c = 11.0482(2)$  Å,  $V = 684.99(2)$  Å<sup>3</sup>,  $Z = 2$ ,  $D_c = 1.925$  Mg m<sup>-3</sup>,  $T = 180(2)$  K. CCDC 787666. *Crystal data for (±)-6b*:  $C_{11}H_{11}Br_2NO_5$ ,  $M = 397.03$ , monoclinic, space group  $P-2(1)/c$ ,  $a = 10.9772(1)$  Å,  $b = 25.2605(3)$  Å,  $c = 10.1567(2)$  Å,  $V = 2725.4(3)$  Å<sup>3</sup>,  $Z = 8$ ,  $D_c = 1.935$  Mg m<sup>-3</sup>,  $T = 180(2)$  K. CCDC 787667.
- 31 Prepared using literature procedure. G. Bartoli, M. Bosco, A. Carlone, M. Locatelli, E. Marcantoni, P. Melchiorre, P. Palazzi and L. Sambri, L., *Eur. J. Org. Chem.*, 2006, 4429.
- 32 See Supplementary Information for <sup>1</sup>H and <sup>13</sup>C NMR spectra of natural and synthetic **1** and **2**.
- 33 P. Ciminiello, V. Costantino, E. Fattorusso, S. Magno, A. Mangoni and M. Pansini, *J. Nat. Prod.*, 1994, **57**, 705.
- 34 In the HMBC spectra of the natural and synthetic samples of **1** and **2**, the quaternary carbon ( $\delta_c$  114.3) couples strongly to the protons H-1 ( $\delta_H$  4.07 and 4.06 respectively) and H-5 ( $\delta_H$  6.42 and 6.40 respectively). However, the quaternary carbon ( $\delta_c$  122.9) only couples to H-5. Therefore the original assignments for C-2 ( $\delta_c$  122.9) and C-4 ( $\delta_c$  114.3) proposed by Habib and co-workers should be switched.
- 35 Both (+)-**6a** ( $t = 30.9$  min) and (–)-**6a** ( $t = 32.9$  min) were converted to their corresponding camphanate esters and their NMR spectral data matched that reported by Nishiyama and co-workers (see Ref. 24).
- 36 The (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay gives a colourimetric measure of the number of viable cells present *in vitro*.